MSLs deployed in launch of Navidea diagnostic agent

Share this article:
MSLs deployed in launch of Navidea diagnostic agent
MSLs deployed in launch of Navidea diagnostic agent

Navidea Biopharmaceuticals is launching Lymphoseek, its diagnostic agent used to check for cancer spread, with medical affairs, promotional education and CME aimed at the nuclear medicine community.

The injection, green-lighted by FDA in March, is the first agent in 30 years to be approved for lymphatic mapping—basically analyzing lymph nodes for signs that a cancer has metastasized. It's sanctioned for use in breast cancer and melanoma. Sulfur Colloid, made by contract manufacturer Pharmalucence, is the only other radiopharmaceutical approved for lymph node localization in these cancers.

Lymphoseek will be sold and distributed in the US exclusively by Cardinal Health through its Nuclear Pharmacy Services. Navidea will deploy medical science liaisons (MSLs) to educate about lymphatic mapping and sentinel node biopsy to hospitals that practice nuclear medicine.

“We have aspirations to participate in the commercial side of the business, but only from a medical-education point of view,” said Thom Tulip, EVP, chief business officer for Navidea. Tulip said the MSL approach “lets us leverage what we learn in the clinic and pharmacy and apply it to not only educate customers to drive adoption [but] also to lift the overall top-line to make the market grow.”

He said Navidea's goal involves expanding Lymphoseek's market to other cancer types that lend themselves to lymphatic mapping. “The mechanism of action is not cancer-specific,” added Tulip, but may apply to “any solid tumor that drains into the lymphatics.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.